163 results on '"Bernard, Léa"'
Search Results
2. A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients
3. Improved outcomes of UM171–expanded cord blood transplantation compared with other graft sources: real-world evidence
4. A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.
5. Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective
6. Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study
7. Seminoma-associated orbitopathy mimicking thyroid-associated orbitopathy: report of a case and literature review.
8. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study
9. UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe Infections
10. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma
11. Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).
12. Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease
13. 1423 Novel immunotherapy based on commensal-derived peptides to drive an effective CD8 T Cell response against selected tumor-associated antigens (TAAs)
14. P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS
15. Seminoma-associated orbitopathy mimicking thyroid-associated orbitopathy: report of a case and literature review
16. Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD
17. Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge
18. Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation
19. Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real World Evidence
20. Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse
21. The EBMT Disease Risk Stratification System (DRSS) Allows Prediction of Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
22. Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
23. Safety and Cost-Effectiveness of Outpatient Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
24. Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study
25. Efficacy, Toxicity and Cost of Venetoclax-Based Combinations for the Treatment of Acute Myeloid Leukemia: Real-World Evidence from a Canadian Academic Center
26. Infusion of UM171-Expanded Cord Blood Led to Excellent Survival in Patients with High-Risk Leukemias: Results from Two Independent Phase II Studies
27. Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)
28. Substitution of Carmustine for Bendamustine in the Transplant Conditioning Regimen Improves Survival in Relapsed/Refractory Lymphoma Patients
29. UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe Infections
30. 41 - A Pilot Study of UM171 Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Stem Cell Transplant in High and Very High-Risk Myeloma Patients
31. Newly diagnosed multiple myeloma patients treated with tandem auto‐allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only
32. Single UM171‐Expanded Cord Blood Transplants Support Robust T‐Cell Reconstitution with Low Rates of Severe Infections
33. Single UM171‐expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors
34. UM171 Expansion Overcomes Shortcomings of Cord Blood Transplantation While Maintaining Benefits
35. Myeloma Patients Relapsing after First Line Treatment with Tandem Auto/Allo Transplant or Auto Transplant Only Have Similar Outcomes.
36. Designing Innovative Management for Cultivated Biodiversity: Lessons from a Pioneering Collaboration between French Farmers, Facilitators and Researchers around Participatory Bread Wheat Breeding
37. Participatory on-farm breeding and management of wheat mixtures
38. UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies
39. Profound MRD negativity rates after frontline tandem autologous-allogeneic stem cell transplantation followed by bortezomib maintenance in high-risk or young myeloma patients
40. 243 - Substitution of Carmustine for Bendamustine in the Transplant Conditioning Regimen Improves Survival in Relapsed/Refractory Lymphoma Patients
41. Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation
42. Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival
43. Single UM171 Expanded Cord Blood Transplant is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality
44. Bortezomib Consolidation after Frontline Auto-Allogeneic Transplant: Low Toxicity and Frequent Immunophenotypic Complete Responses in High-Risk or Young Myeloma Patients
45. Effectiveness of Continuous Infusion of Methylprednisolone for Prevention of Antithymocyte Globulin Infusion-Related Reactions in Preparative Regimens for Allogeneic Hematopoietic Cell Transplantation
46. Pharmacoeconomic Impact and Transplant Outcome Associated to Carmustine (BCNU) Substitution with Bendamustine (Be) in the Conditioning Regimen Prior to Autologous Stem Cell Transplantation for Lymphoma Treatment
47. La thérapie cognitive émotionnelle de groupe dans la gestion des émotions avec des patients borderline
48. Single UM171 Expanded Cord Blood Transplant Is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality
49. Impact of High Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation on the Quality of Life of Elderly Patients Treated for Lymphoma
50. Bortezomib Consolidation after Tandem Auto-Allogeneic Transplantation: High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Newly Diagnosed Myeloma Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.